Case Study 6: Management of Hypertension



Similar documents
Cardiovascular Risk in Diabetes

Hypertension Guideline V4

ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE

Guidelines for the management of hypertension in patients with diabetes mellitus

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Drug Treatment in Type 2 Diabetes with Hypertension

Hypertension Guidelines

Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Case study 28: Managing hypertension in diabetes

High Blood Pressure and Chronic Kidney Disease. For People With CKD Stages 1 4

High Blood pressure and chronic kidney disease

Absolute cardiovascular disease risk management

2013 ACO Quality Measures

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Hypertension and Diabetes

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital

DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

Absolute cardiovascular disease risk

HYPERTENSION MANAGEMENT AND SURVEILLANCE AT PRIMARY CARE LEVEL: A SITUATIONAL ANALYSIS IN THE LIMPOPO PROVINCE

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

High Blood Pressure and Your Kidneys

High Blood Cholesterol

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

High Blood Pressure and Chronic Kidney Disease

Milwaukee School of Engineering Case Study: Factors that Affect Blood Pressure Instructor Version

High Blood Pressure (Essential Hypertension)

Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims

Drug treatment of elevated blood pressure

Getting the most from blood pressure medicines

HIGH BLOOD PRESSURE AND YOUR KIDNEYS

JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

Antihypertensive Drug Management to Achieve Systolic Blood Pressure <120 mmhg in SPRINT

SPECIALTY : CARDIOLOGY CLINICAL PROBLEM: HEART FAILURE

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL

Can Common Blood Pressure Medications Cause Diabetes?

High blood pressure (hypertension)

Diabetes and the Kidneys

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

Absolute cardiovascular disease risk assessment

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

Your Results. For more information visit: Name: Date: In partnership with

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Radiology Business Management Association Technology Task Force. Sample Request for Proposal

Treatment of Hypertension: JNC 8 and More

Case Study 8: Heart Failure

Renal Disease in Type 2 Diabetes Mellitus

Cardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

Chronic Kidney Disease (CKD) Algorithm. Chronic Kidney Disease (CKD) Algorithm Page 1

Hypertension and Heart Failure Medications. Dr William Dooley

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

Clinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW

Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis

Rx Updates New Guidelines, New Medications What You Need to Know

Correspondence to: Rima B Shah (rima_1223@yahoo.co.in) DOI: /ijmsph Received Date: Accepted Date:

Tackling the Semantic Interoperability challenge

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

Appendix: Description of the DIETRON model

HEART HEALTH WEEK 3 SUPPLEMENT. A Beginner s Guide to Cardiovascular Disease HEART FAILURE. Relatively mild, symptoms with intense exercise

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications

Demonstrating Meaningful Use Stage 1 Requirements for Eligible Providers Using Certified EMR Technology

ACCOUNTABLE CARE ORGANIZATION QUICK-REFERENCE SETUP GUIDE

About High Blood Pressure

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME

Cardiovascular Disease Risk Factors

3/2/2010 Post CABG R h e bili a i tat on Ahmed Elkerdany Professor o f oof C ardiac Cardiac Surgery Ain Shams University 1

In many diabetes units, people with type

Easy or complex? University Pharmacy. Pharm.D. candidates, 2011

Psychiatrists and Reporting on Meaningful Use Stage 1. August 6, 2012

How To Treat Dyslipidemia

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Know your Numbers The D5 Goals for Diabetes Care. Shelly Hanson RN, CNS, CDE Cuyuna Regional Medical Center November 6, 2014

Understanding Diseases and Treatments with Canadian Real-world Evidence

High Blood Cholesterol What you need to know

MY TYPE 2 DIABETES NUMBERS

OBJECTIVES AGING POPULATION AGING POPULATION AGING IMPACT ON MEDICARE AGING POPULATION

DIABETES MELLITUS GUIDELINES

Evaluation of anti-hypertensive drug utilisation and cost in Hospital Tengku Ampuan Afzan, Kuantan.

Preconception Clinical Care for Women Medical Conditions

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk

The Canadian Association of Cardiac

Initiate Atorvastatin 20mg daily

Hypertension Best Practices Symposium

Guideline for Microalbuminuria Screening

Cardiovascular risk assessment: Audit findings from a nurse clinic a quality improvement initiative

Transcription:

Case Study 6: Management of Hypertension 2000

Scenario Mr Ellis is a fit 61-year-old, semi-retired market gardener. He is a moderate (10/day) smoker with minimal alcohol intake and there are no other cardiovascular risk factors. His average blood pressure from several readings over the last 4 months is 190/102, despite taking heed of nonpharmacological advice of more exercise and restriction of salt intake. Physical examination is unremarkable. Electrolytes, FBC, lipids, glucose and uric acid tests are normal. There is no history of asthma. At this stage you decide to treat Mr Ellis hypertension. Inside Results page 3 Expert commentary Dr Fred de Looze page 6 Neil Cottrell & Ian Coombes page 9 References page 11 2

Case Study Results Results in summary One hundred and fifty three responses to this case have been received. A sample of one hundred responses has been aggregated to provide a snapshot of how your colleagues responded to this case. The majority of respondents rated Mr Ellis cardiovascular risk level as high (42%)* to very high (32%)*. All respondents chose to write a prescription and 43% of respondents selected angiotensin converting enzyme (ACE) inhibitors as their first choice. 42% of respondents felt that Mr Ellis would benefit from substituting or adding in another drug or drug class to achieve an appropriate blood pressure response. The most frequently chosen agents were thiazide diuretics (13%)* and beta-blockers (11%)*. 28% of respondents identified a third and/or a fourth choice, the most popular being an ACE inhibitors and calcium channel blockers. With drug treatment, 35% of respondents would aim to achieve a target blood pressure of below 130/85 mmhg whilst 62% would be satisfied with a target of 130-140 mmhg systolic and 80-90 mmhg diastolic. If Mr Ellis ECG showed evidence of left ventricular hypertrophy, 50% of respondents would use an alternative agent with 97% favouring to prescribe ACE inhibitors. The remaining 50% of respondents would continue to treat with an initial agent chosen and of those 72% had prescribed ACE inhibitors as first-line. Results in detail Question 1 How would you rate his cardiovascular risk level? low/medium/high/very high rated Mr Ellis cardiovascular risk level as: Cardiovascular risk level Medium 26 High risk 42 Very high risk 32 * Figure in the bracket denotes percentage respondents in case study results. 3

Question 2 If you choose to write a prescription, which agent would you choose? The first choice of agent selected by the respondents were: Agent ACE inhibitor 43 Beta-blocker 17 Calcium channel blocker 12 Angiotensin II receptor antagonist 8 Frusemide 2 42% of respondents identified that they would either substitute or add in another agent. Agent Thiazide diuretic 13 Beta-blocker 11 Calcium channel blocker 10 ACE inhibitor 4 Angiotensin II receptor antagonist 4 A third and fourth choice of antihypertensive agent was identified by 19% and 9% of respondents respectively. Agent 3 rd Choice 4 th Choice ACE inhibitor 3 3 Beta-blocker 3 1 Calcium channel blocker 8 2 Thiazide diuretic 3 0 Angiotensin II receptor antagonist 0 1 Aspirin 2 2 4

Question 3 What would you regard as an appropriate blood pressure response? The blood pressure targets identified by the respondents are shown below with 35% identifying a target blood pressure of < 130/85 mmhg. Target Blood Pressure < 130/85 mmhg 35 130/90 mmhg to 140/80 mmhg 27 140/85 mmhg to 140/90 mmhg 35 > 150/85 mmhg 3 Question 4 Would you prescribe differently for Mr Ellis if an ECG demonstrated left ventricular hypertrophy? Of the respondents 50% would change their initial choice of antihypertensive agent. Of this group, 97% would use ACE inhibitors as their agent of choice. Of the remaining 50% who claimed that they would not change their agent, 72% had already chosen an ACE inhibitor as their initial choice for treatment of Mr Ellis. The table shown below details the remainder of agents chosen as initial therapy and respondents would persue the same treatment unchanged in the light of coexisting complication. Choice Angiotensin II receptor antagonist 13 Thiazide diuretic 7 Beta-blocker 4 Calcium channel blocker 4 5

Expert Commentary Dr Fred de Looze Director, Inala Health Centre General Practice Senior Lecturer in General Practice, University of Queensland Based on the information given in this case study, Mr Ellis is at very high risk (absolute risk (AR) >20%) of experiencing a cardiovascular (CVD) event within the next 5 years. This is based on the fact that he is male, aged > 55 years, smokes and has an average blood pressure of 190/102 mmhg which is classified as severe hypertension. Given that this is the situation and he has been newly diagnosed as having raised blood pressure, his initial management at this consultation should include the following steps if not already performed previously. Initial management Further history: 5 In particular looking for possible causes of his hypertension (recent or past illness involving the kidneys, phaeochromocytoma etc), possible symptoms from end organ involvement and concomitant conditions (e.g. gout) 5 Family history of hypertension, cardiovascular disease, polycystic kidney disease or diabetes. 5 Ingestion of drugs / medications that may raise blood pressure. 5 Allergies / allergic reactions. Physical examination: 5 Height, weight and BMI 5 General appearance (e.g. Conn s, Cushingoid etc) 5 Full cardiovascular examination including fundi and all peripheral pulses 5 Abdominal examination (mass, polycystic kidneys, bruits) Investigations: 5 Urinalysis by dipstick 5 Blood tests (renal function, FBC, lipid profile, glucose and uric acid) 5 ECG 5 CXR 5 Echocardiogram (important to know LV mass, ejection fraction, valve function) 5 Further tests may be indicated based on history and examination findings Initial treatment: 5 Advice about smoking cessation and counselling regarding the significant CVD risk reduction that can be achieved by this. Showing Mr Ellis this by using an AR calculator would most likely be very useful. 5 Dietary advice / information brochures about a low saturated fat diet should be given. The use of plant sterol margarines should be encouraged. 6

Drug management Given that Mr Ellis further history, physical examination and tests are all unremarkable and normal, antihypertensive medication should be started to help lower his blood pressure and other medications considered to help reduce his cardiovascular risk further. This could be done as follows: Antihypertensive drug management: While his blood pressure is very high and it is unlikely that it will be controlled on monotherapy, nevertheless it is prudent to follow the start low, go slow maxim. (There is no indication for lowering his blood pressure rapidly and in fact this is contraindicated in this situation). I would start with a low dose thiazide (e.g. hydrochlorothiazide 25mg) and monitor his response over the next 4 6 weeks. If his blood pressure is still raised, I would add another antihypertensive agent. Given that he is physically active I would choose to use a calcium channel blocker such as nifedipine e.g. Adalat oros (30mg daily) or ACE inhibitor e.g. perindopril (2mg daily) second line rather than a low dose betablocker at this stage. Blood pressure should be reviewed 2 4 weekly to enable dose adjustments to be made. Electrolytes and renal function should be checked after 1 month if adding an ACE inhibitor. Now that diuretic containing combination therapies are available, it could be advantageous thinking about using one of the agents in a combination formulation e.g. Monoplus, Karvezide, Avapro HCT. This would allow Mr Ellis to be changed to a single medication later to assist with adherence to treatment. A third line agent could be added later if indicated to control blood pressure. It is important to monitor for medication side effects as well as response to treatment. His target blood pressure should be 130 138 mmhg systolic and <84 mmhg diastolic. Even if Mr Ellis had left ventricular hypertrophy on ECG I would follow a similar drug management plan although I would lean to an ACE inhibitor second line. This is because the evidence indicates that it is lowering the blood pressure that is the most important thing rather than the agent used to do it. Other medications: 5 Aspirin. On current evidence it would be beneficial to commence low dose aspirin (100 150 mg daily). 5 Depending on the total cholesterol / HDL cholesterol ratio, there may be an indication for medication to lower LDL or raise HDL cholesterol levels after reassessment of the effect of dietary modification. 7

Other management If Mr Ellis blood pressure was difficult to control, it would be necessary to do further investigations looking for secondary causes of hypertension such as renal artery stenosis, hyperaldosteronism or phaechromocytoma. Ambulatory blood pressure monitoring would be indicated. Referral to a hypertension clinic could be considered at this stage. Ongoing monitoring of electrolytes, renal function, glucose and uric acid is indicated when using diuretics. 8

Neil Cottrell Assistant Director of Pharmacy (Clinical) Royal Brisbane Hospital, Brisbane Conjoint Senior Lecturer, University of Queensland NPS Clinical Mentor Ian Coombes Assistant Director of Pharmacy (Clinical) Princess Alexandra Hospital, Brisbane Conjoint Senior Lecturer, University of Queensland NPS Clinical Mentor Question 1 How would you rate his cardiovascular risk level? low/medium/high/very high Considering Mr Ellis risk factors, he has moderate/severe hypertension (SBP 190 mmhg, DBP 102 mmhg), and is a smoker. His cholesterol is assured to be normal and he has no history of diabetes. Mr Ellis has a cardiovascular risk profile between high to very high as shown by 74% of respondents. This means he has between a 15 to > 20% risk of experiencing a cardiovascular event in the next 5 years based on the New Zealand Risk Calculator. 1 Question 2 If you choose to write a prescription, which agent would you choose? It is appropriate to introduce medication at this stage and the choice of agent should be individualised to the patient. From the history of Mr Ellis there appears to be no compelling indications or contraindications to the selection of an agent e.g. gout, diabetes, ischaemic heart disease, or heart failure. Thiazides or a beta-blocker are equal in efficacy to other agents where no specific indication or contraindication exists. 2,3 A thiazide such as very low dose hydrochlorothiazide 12.5mg daily would be an appropriate choice of agent (18%)*. Concerns about effects on lipid profile and sexual dysfunction should be considered and monitored for, but should be balanced by their relatively low incidence when very low doses of thiazides are used. The diuretic effect of low dose thiazides is short lived and usually occurs during the first two to three days of therapy. Their continuing antihypertensive action is related to their vasodilating properties. Monotherapy will usually reduce blood pressure by about 20/10 mmhg and this fall may not be sufficient for Mr Ellis and further medication will be required. The choice of a second agent will help reduce blood pressure and decrease the likelihood of adverse effects i.e. lower doses of two agents. The choice should again be based on the individual patient, and a beta-blocker (11%)* or a long acting calcium channel blocker (10%)*, would be appropriate. * Figure in the bracket denotes percentage respondents in case study results. 9

From the case responses it is interesting that the antihypertensive chosen by 43% was an ACE inhibitor. It is important to remember that all antihypertensives are equally effective at lowering blood pressure and reducing cardiovascular events, 2 in the population such as Mr Ellis who do not have compelling indications or contraindications to specific therapy. Question 3 What would you regard as an appropriate blood pressure response? In deciding on the ideal target blood pressure the following factors need to be considered: such as age < 65 years, presence of renal insufficiency or presence of diabetes. Any or all of which would suggest an ideal target of < 130/85 mmhg. 4 In Mr Ellis case the single factor of age < 65 years would suggest a target of <130/85 mmhg to help to reduce his long-term risk of experiencing cardiovascular event. This was the level selected by 35% of respondents. It is important to ensure that Mr Ellis will tolerate this degree of blood pressure lowering and this concern is reflected by the 27% of respondents who would aim for a target blood pressure of 130/90 mmhg to 140/80 mmhg. Question 4 Would you prescribe differently for Mr Ellis if an ECG demonstrated left ventricular hypertrophy? There is no evidence to change your initial choice of antihypertensive agent(s) for Mr Ellis. Although he has an indication of left ventricular hypertrophy on his ECG (an expected complication of uncontrolled hypertension) he exhibits no signs or symptoms of heart failure. The current evidence is that all classes of agent (thiazide, beta-blocker, calcium channel blocker, alpha-blocker and ACE inhibitor) reduced left ventricular mass per se and where no compelling indication or contraindication still existed a thiazide would be suitable. 2 If there were any concerns that pre-clinical/asymptomatic heart failure existed (may only be picked up through reduced ejection fraction as shown on echocardiogram) that would be a compelling indication for using an ACE inhibitor. 10

References 1. The National Heart Foundation of New Zealand. New Zealand Risk Calculator. 2. Neaton JD, Grimm RH, et al. Treatment of Mild Hypertension Study. JAMA 1993;270:713-24. 3. Hansson L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril prevention project (CAPPP) randomized trial. Lancet 1999;353:611-16. 4. National Heart Foundation of Australia. 1999 Guide to Management of Hypertension for Doctors. 11